The marked reduction in tumor spheroid size observed following mitoxantrone treatment in both EGFR- and TLR-stimulated conditions strongly suggests that USP11 is a promising therapeutic target for EGFR- or TLR-driven CRC. Here, EGFR is linked to neoplasm.